Remove 2007 Remove Biosimilars Remove Drug Pricing
article thumbnail

Why the drug pricing debate is focused on insulin

pharmaphorum

The organisation noted that the average net cost of these insulin products is 20% lower than in 2007. Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients. Potential biosimilar impact. Innovation to end debate?

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

Formulary Inclusion and Placement of Generics and Biosimilars The NHC supports CMS proposals to improve formulary practices by prioritizing access to generics, biosimilars, and other cost-effective medications in the Medicare Part D program.